Thursday, October 4, 2018: 10:30 AM-11:45 AM
Room: S 151-153
Moderators:
Monica Gandhi, MD, MPH, Division of HIV, Infectious Diseases and Global Medicine, UCSF
and
Jodie Dionne-Odom, MD, 703 19th Street South
Presentations:
10:30 AM
Doravirine/Lamivudine/Tenofovir DF continues to be Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-naïve Adults with HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
Chloe Orkin, MBBCh;
Kathleen Squires, MD;
Jean-Michel Molina, MD;
Paul Sax, MD;
Wingwai Wong, MD;
Otto Sussmann, MD;
Gina Lin, MS;
Sushma Kumar, PhD;
George Hanna, MD;
Carey Hwang, MD, PhD;
Elizabeth Martin, DO, MPH;
Hedy Teppler, MD
10:40 AM
Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Princy Kumar, M.D.;
Margaret Johnson, MD, FRCP;
Jean-Michel Molina, MD;
Giuliano Rizzardini, MD;
Pedro Cahn, MD, PhD;
Markus Bickel, MD;
Josep Mallolas, MD;
Yan Zhou, PhD;
Cristiana Morais, PhD;
Sushma Kumar, PhD;
Peter Sklar, MD, MPH;
George J. Hanna, MD;
Carey Hwang, MD, PhD;
Wayne Greaves, MD
10:50 AM
Daptomycin plus Fosfomycin versus Daptomycin Monotherapy for Methicillin-resistant Staphylococcus aureus Bacteremia. A Multicenter, Randomized, Clinical Trial
Miquel Pujol, MD, PhD;
Jose-Maria Miro, MD, PhD;
Evelyn Shaw, MD, PhD;
Jose Maria Aguado, MD, PhD;
Rafael San-Juan Garrido, MD, PhD;
Mireia Puig, MD, PhD;
Carle Pigrau, MD, PhD;
Esther Calbo, MD, PhD;
Jose Miguel Montejo, MD, PhD;
Regino Rodriguez, MD;
Maria Jose Garcia-Pais, MD;
Vicente Pintado, MD, PhD;
Rosa Escudero, MD;
Joaquin Lopez-Contreras, MD, PhD;
Laura Morata, MD;
Milagro Montero, MD, PhD;
Marta Andres, MD;
Juan Pasquau, MD, PhD;
Belen Padilla, MD, PhD;
Javier Murillas, MD, PhD;
Alfredo Jover, MD, PhD;
Luis Eduardo Lopez-Cortes, MD, PhD;
Graciano Garcia-Pardo, MD;
Oriol Gasch, MD, PhD;
Sebastian Videla, MD, PhD;
Cristian Tebe, MSc;
Natalia Pallares, MSc;
Pilar Hereu, MD, PhD;
Mireia Sanllorente, MSc;
Maria Angeles Dominguez, MD, PhD;
Jordi Camara, MD;
Ariadna Padulles, MD, PhD;
Jordi Carratala, MD, PhD
11:00 AM
A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs ABC/DTG/3TC in Treatment-Naïve Adults at Week 96
David A. Wohl, MD;
Yazdan Yazdanpanah, MD;
Axel Baumgarten, MD;
Amanda Clarke, M.D.;
Melanie Thompson, MD;
Cynthia Brinson, M.D.;
Debbie Hagins, MD;
Moti Ramgopal, MD, FACP, FIDSA;
Andrea Antinori, MD;
Xuelian Wei, PhD;
Kirsten White, PhD;
Sean Collins, MD;
Andrew Cheng, MD PhD;
Erin Quirk, MD;
Hal Martin, MD, MPH
11:20 AM
Oral Lefamulin Is Safe and Effective in the Treatment of Adults with Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
Elizabeth Alexander, MD;
Lisa Goldberg, MS;
Anita Das, PhD;
Gregory J. Moran, MD;
Christian Sandrock, MD;
Leanne B. Gasink, MD;
Patricia Spera, PhD;
Carolyn Sweeney, BS;
Susanne Paukner, PhD;
Wolfgang W. Wicha, MS;
Jennifer Schranz, MD
CME Credits: Maximum of 0.00 hours of
AMA PRA Category 1 Credit™
